Inclusion Criteria:

- Diagnosis of CTCL stages IA-IIA by histopathology and immunohistochemistry in
screening biopsies confirmed at Case Western Reserve University within 6 months of
enrollment; biopsies may be performed at the site of collaborating institutions and
shipped to UHC-CWRU

- Performance status ECOG grade 0, 1, or 2

- Patients must have recovered from toxicity of prior treatment and have received no
CTCL therapy other than emolliation for at least 4 weeks, with the exception of
topical corticosteroids, which may be used up to 2 weeks before the trial start date

- Patients must have signed a consent form indicating the investigational nature of the
treatment and its potential side effects

- WBC > 4,000/ul

- ANC > 2000/ul

- Platelets > 100,000/ul

- Bilirubin < 1.5 mg/dL

- SGOT within normal range

- Creatinine =< 1.5 mg/dL

- Electrolytes normal

- Controlled (diet and insulin) diabetes is permitted

- Demonstration of clinically normal lung function based on history and physical
examination; patients with clinical evidence of pulmonary disease as determined by
the investigator should have baseline lung function tests performed with
demonstration of DLCO > 80%; a DLCO single breath, adjusted for hemoglobin, will be
utilized; we will not use DLCO/VA for inclusion or exclusion in this study

- Patients must have cutaneous disease that is amenable to biopsy and must be willing
to undergo several sequential biopsies

- Must have failed at least one conventional treatment for CTCL other than topical
corticosteroids; this includes phototherapy, topical mechlorethamine, topical or oral
bexarotene, radiation therapy, photopheresis, chemotherapy, and immunomodulatory
agents such as interferon and other retinoids

Exclusion Criteria:

- Patients who have received prior treatment with topical or systemic BCNU or other
nitrosoureas

- Patients with known central nervous system involvement or primary CNS malignancies

- Patients with performance status ECOG grade 3 or 4

- Pregnant women, women who are breast feeding infants, or women with reproductive
potential not practicing adequate contraception, because of potential toxicity to the
fetus or infant

- Patients with an active infection which requires hospitalization, or which may affect
the patient's safety if the patient was enrolled

- Patients with pulmonary disease as determined by history, physical examination, chest
X-ray, or pulse oximetry with DLCO < 80%

- CTCL patients with stage IIB-IVB disease